Oncolytic HSV-1 virotherapy: Clinical experience and opportunities for progress

Current Pharmaceutical Biotechnology

Volumn 13, Issue 9, 2012, Pages 1842-1851

  Kaur, Balveen ^a   Chiocca, E Antonio ^a   Cripe, Timothy P ^b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Angiogenesis; Cytokines; Extracellular matrix; Herpes simplex virus; Immune response; Oncolytic viruses; Tumor microenvironment

Indexed keywords

ONCOLYTIC HERPES VIRUS;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; HERPES SIMPLEX VIRUS 1; HERPES VIRUS INFECTION; HUMAN; NEOPLASM; NONHUMAN; ONCOLYTIC VIROTHERAPY; VIRUS MUTANT;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HERPESVIRUS 1, HUMAN; HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES;

HUMAN HERPESVIRUS 1; SIMPLEXVIRUS;

EID: 84863550194     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112800958814     Document Type: Article

References (113)

1. Liu, T. C.; Galanis, E.; Kirn, D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat. Clin. Pract. Oncol., 2007 4, 101-117.
2. Levaditi, C.; Nicolau, S. Affinite du virus herpetique pour les neoplasmes epitheliaux. Compt. Rend. Soc. De. Biol., 1922 87, 498-500.
3. Aghi, M.; Visted, T.; Depinho, R. A.; Chiocca, E. A. Oncolytic herpes virus with defective ICP6 specifically repli cates in quiescent cells with homozygous genetic mutations in p16. Oncogene, 2008, 27(30), 4249-4254
4. Martuza, R. L.; Malick, A.; Markert, J. M.; Ruffner, K. L.; Coen, D. M. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science, 1991 252, 854-856.
5. Goldstein, D. J.; Weller, S. K. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J. Virol, 1988 62, 196-205.
6. Kasuya, H.; Nishiyama, Y.; Nomoto, S.; Hosono, J.; Takeda, S.; Nakao, A. Intraperitoneal delivery of hrR3 and ganciclovir prolongs survival in mice with disseminated pancreatic cancer. J. Surg. Oncol., 1999 72, 136-141.
7. Mineta, T.; Rabkin, S. D.; Martuza, R. L. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductasedeficient herpes simplex viral mutant. Cancer Res., 1994 54, 3963-3966.
8. Boviatsis, E. J.; Park, J. S.; Sena-Esteves, M.; Kramm, C. M.; Chase, M.; Efird, J. T.; Wei, M. X.; Breakefield, X. O.; Chiocca, E. A. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res., 1994 54, 5745-5751.
9. Todo, T.; Rabkin, S. D.; Martuza, R. L. Evaluation of ganciclovirmediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors. Cancer Gene. Ther., 2000 7, 939-946.
10. Kurozumi, K.; Hardcastle, J.; Thakur, R.; Yang, M.; Christoforidis, G.; Fulci, G.; Hochberg, F. H.; Weissleder, R.; Carson, W.; Chiocca, E. A.; Kaur, B. Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J. Natl. Cancer Inst., 2007 99, 1768-1781.
11. Spear, M. A.; Sun, F.; Eling, D. J.; Gilpin, E.; Kipps, T. J.; Chiocca, E. A.; Bouvet, M. Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation. Cancer Gene. Ther., 2000 7, 1051-1059.
12. Aghi, M.; Rabkin, S.; Martuza, R. L. Oncolytic herpes simplex virus mutants exhibit enhanced replication in glioma cells evading temozolomide chemotherapy through deoxyribonucleic acid repair. Clin. Neurosurg., 2006 53, 65-76.
13. Yamada, Y.; Kimura, H.; Morishima, T.; Daikoku, T.; Maeno, K.; Nishiyama, Y. The pathogenicity of ribonucleotide reductase-null mutants of herpes simplex virus type 1 in mice. J. Infect. Dis., 1991 164, 1091-1097.
14. Ikeda, K.; Wakimoto, H.; Ichikawa, T.; Jhung, S.; Hochberg, F. H.; Louis, D. N.; Chiocca, E. A. Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication conditional herpes simplex virus mutant. J. Virol., 2000 74, 4765-4775.
15. Nakamura, H.; Kasuya, H.; Mullen, J. T.; Yoon, S. S.; Pawlik, T. M.; Chandrasekhar, S.; Donahue, J. M.; Chiocca, E. A.; Chung, R. Y.; Tanabe, K. K. Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5. J. Clin. Invest., 2002 109, 871-882.
16. Aghi, M.; Chou, T. C.; Suling, K.; Breakefield, X. O.; Chiocca, E. A. Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res, 1999 59, 3861-3865.
17. Pawlik, T. M.; Nakamura, H.; Mullen, J. T.; Kasuya, H.; Yoon, S. S.; Chandrasekhar, S.; Chiocca, E. A.; Tanabe, K. K. Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene. Cancer, 2002 95, 1171-1181.
18. Currier, M. A.; Gillespie, R. A.; Sawtell, N. M.; Mahller, Y. Y.; Stroup, G.; Collins, M. H.; Kambara, H.; Chiocca, E. A.; Cripe, T. P. Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide. Mol. Ther., 2008 16, 879-885.
19. Pawlik, T. M.; Nakamura, H.; Yoon, S. S.; Mullen, J. T.; Chandrasekhar, S.; Chiocca, E. A.; Tanabe, K. K. Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus. Cancer Res., 2000 60, 2790-2795.
20. Eshun, F.; Currier, M.; Gillespie, R.; Fitzpatrick, J.; Baird, W.; Cripe, T. VEGF blockade decreases tumor uptake of systemic oncolytic Herpes virus but enhances therapeutic efficacy when given after virotherapy. Gene. Ther., 2010, 17(7), 922-929.
21. Chou, J.; Kern, E. R.; Whitley, R. J.; Roizman, B. Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science, 1990 250, 1262-1266.
22. Bolovan, C. A.; Sawtell, N. M.; Thompson, R. L. ICP34.5 mutants of herpes simplex virus type 1 strain 17syn+ are attenuated for neurovirulence in mice and for replication in confluent primary mouse embryo cell cultures. J. Virol., 1994, 68, 48-55.
23. McKie, E. A.; MacLean, A. R.; Lewis, A. D.; Cruickshank, G.; Rampling, R.; Barnett, S. C.; Kennedy, P. G.; Brown, S. M. Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours--evaluation of a potentially effective clinical therapy. Br. J. Cancer, 1996 74, 745-752.
24. Lasner, T. M.; Kesari, S.; Brown, S. M.; Lee, V. M.; Fraser, N. W.; Trojanowski, J. Q. Therapy of a murine model of pediatric brain tumors using a herpes simplex virus type-1 ICP34.5 mutant and demonstration of viral replication within the CNS. J. Neuropathol. Exp. Neurol., 1996 55, 1259-1269.
25. Kesari, S.; Randazzo, B. P.; Valyi-Nagy, T.; Huang, Q. S.; Brown, S. M.; MacLean, A. R.; Lee, V. M.; Trojanowski, J. Q.; Fraser, N. W. Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. Lab. Invest., 1995 73, 636-648.
26. Rampling, R.; Cruickshank, G.; Papanastassiou, V.; Nicoll, J.; Hadley, D.; Brennan, D.; Petty, R.; MacLean, A.; Harland, J.; McKie, E.; Mabbs, R.; Brown, M. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene. Ther., 2000 7, 859-866.
27. Harland, J.; Papanastassiou, V.; Brown, S. M. HSV1716 persistence in primary human glioma cells in vitro. Gene. Ther., 2002 9, 1194-1198.
28. Papanastassiou, V.; Rampling, R.; Fraser, M.; Petty, R.; Hadley, D.; Nicoll, J.; Harland, J.; Mabbs, R.; Brown, M. The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene. Ther., 2002 9, 398-406.
29. Harrow, S.; Papanastassiou, V.; Harland, J.; Mabbs, R.; Petty, R.; Fraser, M.; Hadley, D.; Patterson, J.; Brown, S. M.; Rampling, R. HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene. Ther., 2004 11, 1648-1658.
30. MacKie, R. M.; Stewart, B.; Brown, S. M. Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet, 2001 357, 525-526.
31. Mace, A. T.; Ganly, I.; Soutar, D. S.; Brown, S. M. Potential for efficacy of the oncolytic Herpes simplex virus 1716 in patients with oral squamous cell carcinoma. Head Neck, 2008 30, 1045-1051.
32. Mace, A. T.; Harrow, S. J.; Ganly, I.; Brown, S. M. Cytotoxic effects of the oncolytic herpes simplex virus HSV1716 alone and in combination with cisplatin in head and neck squamous cell carcinoma. Acta Otolaryngol., 2007 127, 880-887.
33. Yu, Z.; Adusumilli, P. S.; Eisenberg, D. P.; Darr, E.; Ghossein, R. A.; Li, S.; Liu, S.; Singh, B.; Shah, J. P.; Fong, Y.; Wong, R. J. Nectin-1 expression by squamous cell carcinoma is a predictor of herpes oncolytic sensitivity. Mol. Ther., 2007 15, 103-113.
34. Yu, Z.; Li, S.; Huang, Y. Y.; Fong, Y.; Wong, R. J. Calcium depletion enhances nectin-1 expression and herpes oncolytic therapy of squamous cell carcinoma. Cancer Gene. Ther., 2007 14, 738-747.
35. Bharatan, N. S.; Currier, M. A.; Cripe, T. P. Differential susceptibility of pediatric sarcoma cells to oncolysis by conditionally replication-competent herpes simplex viruses. J. Pediatr. Hematol. Oncol., 2002 24, 447-453.
36. Parikh, N. S.; Currier, M. A.; Mahller, Y. Y.; Adams, L. C.; Di Pasquale, B.; Collins, M. H.; Cripe, T. P. Oncolytic herpes simplex virus mutants are more efficacious than wild-type adenovirus Type 5 for the treatment of high-risk neuroblastomas in preclinical models. Pediatr. Blood Cancer, 2005 44, 469-478.
37. Currier, M. A.; Adams, L. C.; Mahller, Y. Y.; Cripe, T. P. Widespread intratumoral virus distribution with fractionated injection enables local control of large human rhabdomyosarcoma xenografts by oncolytic herpes simplex viruses. Cancer Gene. Ther., 2005 12, 407-416.
38. Mahller, Y. Y.; Vaikunth, S. S.; Currier, M. A.; Miller, S. J.; Ripberger, M. C.; Hsu, Y. H.; Mehrian-Shai, R.; Collins, M. H.; Crombleholme, T. M.; Ratner, N.; Cripe, T. P. Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model. Mol. Ther., 2007 15, 279-286.
39. Mahller, Y. Y.; Rangwala, F.; Ratner, N.; Cripe, T. P. Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants. Pediatr. Blood Cancer, 2006 46, 745-754.
40. Eshun, F. K.; Currier, M. A.; Gillespie, R. A.; Fitzpatrick, J. L.; Baird, W. H.; Cripe, T. P. VEGF blockade decreases the tumor uptake of systemic oncolytic herpes virus but enhances therapeutic efficacy when given after virotherapy. Gene Ther.,2010, 17(7), 922-929.
41. Mineta, T.; Rabkin, S. D.; Yazaki, T.; Hunter, W. D.; Martuza, R.L. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med., 1995 1, 938-943.
42. Bennett, J. J.; Delman, K. A.; Burt, B. M.; Mariotti, A.; Malhotra, S.; Zager, J.; Petrowsky, H.; Mastorides, S.; Federoff, H.; Fong, Y. Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer. Cancer Gene. Ther., 2002 9, 935-945.
43. Huszthy, P. C.; Immervoll, H.; Wang, J.; Goplen, D.; Miletic, H.; Eide, G. E.; Bjerkvig, R. Cellular effects of oncolytic viral therapy on the glioblastoma microenvironment. Gene Ther., 2010 17, 202-216.
44. Radbill, A. E.; Reddy, A. T.; Markert, J. M.; Wyss, J. M.; Pike, M. M.; Akella, N. S.; Bharara, N.; Gillespie, G. Y. Effects of G207, a conditionally replication-competent oncolytic herpes simplex virus, on the developing mammalian brain. J. Neurovirol., 2007 13, 118-129.
45. Markert, J. M.; Medlock, M. D.; Rabkin, S. D.; Gillespie, G. Y.; Todo, T.; Hunter, W. D.; Palmer, C. A.; Feigenbaum, F.; Tornatore, C.; Tufaro, F.; Martuza, R. L. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther., 2000 7, 867-874.
46. Meignier, B.; Longnecker, R.; Roizman, B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J. Infect. Dis., 1988 158, 602-614.
47. Advani, S. J.; Chung, S. M.; Yan, S. Y.; Gillespie, G. Y.; Markert, J. M.; Whitley, R. J.; Roizman, B.; Weichselbaum, R. R. Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors. Cancer Res., 1999 59, 2055-2058.
48. Cozzi, P. J.; Malhotra, S.; McAuliffe, P.; Kooby, D. A.; Federoff, H.J.; Huryk, B.; Johnson, P.; Scardino, P. T.; Heston, W. D.; Fong, Y. Intravesical oncolytic viral therapy using attenuated, replicationcompetent herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model. FASEB J., 2001 15, 1306-1308.
49. Cozzi, P. J.; Burke, P. B.; Bhargav, A.; Heston, W. D.; Huryk, B.; Scardino, P. T.; Fong, Y. Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses. Prostate, 2002 53, 95-100.
50. Wong, R. J.; Kim, S. H.; Joe, J. K.; Shah, J. P.; Johnson, P. A.; Fong, Y. Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus. J. Am. Coll. Surg., 2001 193, 12-21.
51. Delman, K. A.; Bennett, J. J.; Zager, J. S.; Burt, B. M.; McAuliffe, P. F.; Petrowsky, H.; Kooby, D. A.; Hawkins, W. G.; Horsburgh, B. C.; Johnson, P.; Fong, Y. Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy. Hum. Gene. Ther., 2000 11, 2465-2472.
52. Kemeny, N.; Brown, K.; Covey, A.; Kim, T.; Bhargava, A.; Brody, L.; Guilfoyle, B.; Haag, N. P.; Karrasch, M.; Glasschroeder, B.; Knoll, A.; Getrajdman, G.; Kowal, K. J.; Jarnagin, W. R.; Fong, Y. Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum. Gene Ther., 2006 17, 1214-1224.
53. Fong, Y.; Kim, T.; Bhargava, A.; Schwartz, L.; Brown, K.; Brody, L.; Covey, A.; Karrasch, M.; Getrajdman, G.; Mescheder, A.; Jarnagin, W.; Kemeny, N. A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer. Mol. Ther., 2009 17, 389-394.
54. Nawa, A.; Luo, C.; Zhang, L.; Ushjima, Y.; Ishida, D.; Kamakura, M.; Fujimoto, Y.; Goshima, F.; Kikkawa, F.; Nishiyama, Y. Nonengineered, naturally oncolytic herpes simplex virus HSV1 HF-10: applications for cancer gene therapy. Curr. Gene Ther., 2008 8, 208-221.
55. Ushijima, Y.; Luo, C.; Goshima, F.; Yamauchi, Y.; Kimura, H.; Nishiyama, Y. Determination and analysis of the DNA sequence of highly attenuated herpes simplex virus type 1 mutant HF10, a potential oncolytic virus. Microbes. Infect., 2007 9, 142-149.
56. Teshigahara, O.; Goshima, F.; Takao, K.; Kohno, S.; Kimata, H.; Nakao, A.; Nishiyama, Y. Oncolytic viral therapy for breast cancerwith herpes simplex virus type 1 mutant HF 10. J. Surg. Oncol., 2004 85, 42-47.
57. Ogawa, F.; Takaoka, H.; Iwai, S.; Aota, K.; Yura, Y. Combined oncolytic virotherapy with herpes simplex virus for oral squamous cell carcinoma. Anticancer Res., 2008 28, 3637-3645.
58. Takakuwa, H.; Goshima, F.; Nozawa, N.; Yoshikawa, T.; Kimata, H.; Nakao, A.; Nawa, A.; Kurata, T.; Sata, T.; Nishiyama, Y. Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice. Arch. Virol., 2003 148, 813-825.
59. Tolba, K. A.; Bowers, W. J.; Hilchey, S. P.; Halterman, M. W.; Howard, D. F.; Giuliano, R. E.; Federoff, H. J.; Rosenblatt, J. D. Development of herpes simplex virus-1 amplicon-based immunotherapy for chronic lymphocytic leukemia. Blood, 2001 98, 287-295.
60. Shimoyama, S.; Goshima, F.; Teshigahara, O.; Kasuya, H.; Kodera, Y.; Nakao, A.; Nishiyama, Y. Enhanced efficacy of herpes simplex virus mutant HF10 combined with paclitaxel in peritoneal cancer dissemination models. Hepatogastroenterology, 2007 54, 1038-1042.
61. Kimata, H.; Imai, T.; Kikumori, T.; Teshigahara, O.; Nagasaka, T.; Goshima, F.; Nishiyama, Y.; Nakao, A. Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer. Ann. Surg. Oncol., 2006 13, 1078-1084.
62. Fujimoto, Y.; Mizuno, T.; Sugiura, S.; Goshima, F.; Kohno, S.; Nakashima, T.; Nishiyama, Y. Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma. Acta Otolaryngol., 2006 126, 1115-1117.
63. Liu, B. L.; Robinson, M.; Han, Z. Q.; Branston, R. H.; English, C.; Reay, P.; McGrath, Y.; Thomas, S. K.; Thornton, M.; Bullock, P.; Love, C. A.; Coffin, R. S. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther., 2003 10, 292-303.
64. Cassady, K. A.; Gross, M. The herpes simplex virus type 1 U(S)11 protein interacts with protein kinase R in infected cells and requires a 30-amino-acid sequence adjacent to a kinase substrate domain. J. Virol., 2002 76, 2029-2035.
65. Cassady, K A; Gross, M; Roizman, B. The herpes simplex virus US11 protein effectively compensates for the gamma1(34.5) gene if present before activation of protein kinase R by precluding its phosphorylation and that of the alpha subunit of eukaryotic translation initiation factor 2. J. Virol., 1998 72, 8620-8626.
66. Cassel, W. A.; Garrett, R. E. Newcastle Disease Virus As An Antineoplastic Agent. Cancer, 1965 18, 863-868.
67. Hu, J. C.; Coffin, R. S.; Davis, C. J.; Graham, N. J.; Groves, N.; Guest, P. J.; Harrington, K. J.; James, N. D.; Love, C. A.; McNeish, I.; Medley, L. C.; Michael, A.; Nutting, C. M.; Pandha, H. S.; Shorrock, C. A.; Simpson, J.; Steiner, J.; Steven, N. M.; Wright, D.; Coombes, R. C. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin. Cancer Res., 2006 12, 6737-6747.
68. Senzer, N. N.; Kaufman, H. L.; Amatruda, T.; Nemunaitis, M.; Reid, T.; Daniels, G.; Gonzalez, R.; Glaspy, J.; Whitman, E.; Harrington, K.; Goldsweig, H.; Marshall, T.; Love, C.; Coffin, R.; Nemunaitis, J. J. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J. Clin. Oncol., 2009 27, 5763-5771.
69. Kaufman, H. L.; Kim, D. W.; DeRaffele, G.; Mitcham, J.; Coffin, R. S.; Kim-Schulze, S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann. Surg. Oncol., 2010 17, 718-730.
70. Markert, J. M.; Liechty, P. G.; Wang, W.; Gaston, S.; Braz, E.; Karrasch, M.; Nabors, L. B.; Markiewicz, M.; Lakeman, A. D.; Palmer, C. A.; Parker, J. N.; Whitley, R. J.; Gillespie, G. Y. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and posttumor resection for recurrent GBM. Mol. Ther., 2009 17, 199-207.
71. Ikeda, K.; Ichikawa, T.; Wakimoto, H.; Silver, J. S.; Deisboeck, T. S.; Finkelstein, D.; Harsh, G. R. T.; Louis, D. N.; Bartus, R. T.; Hochberg, F. H.; Chiocca, E. A. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat. Med., 1999 5, 881-887.
72. Daher, K. A.; Selsted, M. E.; Lehrer, R. I. Direct inactivation of viruses by human granulocyte defensins. J. Virol., 1986 60, 1068-1074.
73. Lundy, F. T.; Orr, D. F.; Gallagher, J. R.; Maxwell, P.; Shaw, C.; Napier, S. S.; Gerald Cowan, C.; Lamey, P. J.; Marley, J. J. Identification and overexpression of human neutrophil alphadefensins (human neutrophil peptides 1, 2 and 3) in squamous cell carcinomas of the human tongue. Oral. Oncol., 2004 40, 139-144.
74. Steinstraesser, L.; Hauk, J.; Schubert, C.; Al-Benna, S.; Stricker, I.; Hatt, H.; Shai, Y.; Steinau, H. U.; Jacobsen, F. Suppression of soft tissue sarcoma growth by a host defense-like lytic Peptide. PLoS One, 2011 6, e18321.
75. Yu, Z.; Li, S.; Huang, Y. Y.; Lin, S. F.; Fong, Y.; Wong, R. J. Sensitivity of squamous cell carcinoma lymph node metastases to herpes oncolytic therapy. Clin. Cancer Res., 2008 14, 1897-1904.
76. Conner, J.; Braidwood, L.; Brown, S. M. A strategy for systemic delivery of the oncolytic herpes virus HSV1716: redirected tropism by antibody-binding sites incorporated on the virion surface as a glycoprotein D fusion protein. Gene. Ther., 2008 15, 1579-1592.
77. Nakano, K.; Kobayashi, M.; Nakamura, K.; Nakanishi, T.; Asano, R.; Kumagai, I.; Tahara, H.; Kuwano, M.; Cohen, J. B.; Glorioso, J. C. Mechanism of HSV infection through soluble adapter-mediated virus bridging to the EGF receptor. Virology, 2011 413, 12-18.
78. Baek, H.; Uchida, H.; Jun, K.; Kim, J. H.; Kuroki, M.; Cohen, J. B.; Glorioso, J. C.; Kwon, H. Bispecific adapter-mediated retargeting of a receptor-restricted HSV-1 vector to CEA-bearing tumor cells. Mol. Ther., 2011 19, 507-514.
79. Cripe, T. P.; Wang, P. Y.; Marcato, P.; Mahller, Y. Y.; Lee, P. W. Targeting cancer-initiating cells with oncolytic viruses. Mol. Ther., 2009 17, 1677-1682.
80. Kanai, R.; Wakimoto, H.; Martuza, R. L.; Rabkin, S. D. A novel oncolytic herpes simplex virus that synergizes with phosphatidylinositol 3-kinase/akt pathway inhibitors to target glioblastoma stem cells. Clin. Cancer Res., 2011, 17(11),3686-3696.
81. Vangipuram, S. D.; Wang, Z. J.; Lyman, W. D. Resistance of stemlike cells from neuroblastoma cell lines to commonly used chemotherapeutic agents. Pediatr. Blood Cancer, 2010 54, 361-368.
82. Friedman, G. K.; Langford, C. P.; Coleman, J. M.; Cassady, K. A.; Parker, J. N.; Markert, J. M.; Yancey Gillespie, G. Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111. J. Neurooncol., 2009 95, 199-209.
83. Wakimoto, H.; Kesari, S.; Farrell, C. J.; Curry, W. T. Jr.; Zaupa, C.; Aghi, M.; Kuroda, T.; Stemmer-Rachamimov, A.; Shah, K.; Liu, T. C.; Jeyaretna, D. S.; Debasitis, J.; Pruszak, J.; Martuza, R. L.; Rabkin, S. D. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res., 2009 69, 3472-3481.
84. Hardcastle, J; Kurozumi, K; Chiocca, E A; Kaur, B. Oncolytic viruses driven by tumor-specific promoters. Curr. Cancer Drug Targets, 2007, 7, 181-189.
85. Kambara, H.; Okano, H.; Chiocca, E. A.; Saeki, Y. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res., 2005 65, 2832-2839.
86. Mahller, Y. Y.; Williams, J. P.; Baird, W. H.; Mitton, B.; Grossheim, J.; Saeki, Y.; Cancelas, J. A.; Ratner, N.; Cripe, T. P. Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS ONE, 2009 4, e4235.
87. Kambara, H.; Saeki, Y.; Chiocca, E. A. Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus. Cancer Res., 2005 65, 11255-11258.
88. Valyi-Nagy, K.; Dosa, S.; Kovacs, S. K.; Bacsa, S.; Voros, A.; Shukla, D.; Folberg, R.; Valyi-Nagy, T. Identification of virus resistant tumor cell subpopulations in three-dimensional uveal melanoma cultures. Cancer Gene. Ther., 2009, 17(4),223-234.
89. Kamoun, W. S.; Ley, C. D.; Farrar, C. T.; Duyverman, A. M.; Lahdenranta, J.; Lacorre, D. A.; Batchelor, T. T.; di Tomaso, E.; Duda, D. G.; Munn, L. L.; Fukumura, D.; Sorensen, A. G.; Jain, R. K. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J. Clin. Oncol., 2009 27, 2542-2552.
90. Fukumura, D.; Jain, R. K. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc. Res., 2007 74, 72-84.
91. Netti, P. A.; Berk, D. A.; Swartz, M. A.; Grodzinsky, A. J.; Jain, R. K. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res., 2000 60, 2497-2503.
92. Vargova, L.; Homola, A.; Zamecnik, J.; Tichy, M.; Benes, V.; Sykova, E. Diffusion parameters of the extracellular space in human gliomas. Glia, 2003 42, 77-88.
93. Sauthoff, H.; Hu, J.; Maca, C.; Goldman, M.; Heitner, S.; Yee, H.; Pipiya, T.; Rom, W. N.; Hay, J. G. Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time points. Hum. Gene. Ther., 2003 14, 425-433.
94. Markert, J. M.; Liechty, P. G.; Wang, W.; Gaston, S.; Braz, E.; Karrasch, M.; Nabors, L. B.; Markiewicz, M.; Lakeman, A. D.; Palmer, C. A.; Parker, J. N.; Whitley, R. J.; Gillespie, G. Y. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol. Ther., 2008, 17(1),199-207
95. Kuriyama, N; Kuriyama, H; Julin, C M; Lamborn, K; Israel, M A. Pretreatment with protease is a useful experimental strategy for enhancing adenovirus-mediated cancer gene therapy. Hum. Gene. Ther., 2000 11, 2219-2230.
96. Ganesh, S.; Gonzalez-Edick, M.; Gibbons, D.; Van Roey, M.; Jooss, K. Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models. Clin. Cancer Res., 2008 14, 3933-3941.
97. McKee, T. D.; Grandi, P.; Mok, W.; Alexandrakis, G.; Insin, N.; Zimmer, J. P.; Bawendi, M. G.; Boucher, Y.; Breakefield, X. O.; Jain, R. K. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res., 2006 66, 2509-2513.
98. Dmitrieva, N.; Yu, L.; Viapiano, M.; Cripe, T P; Chiocca, E A; Glorioso, J C; Kaur, B. Chondroitinase ABC I-mediated enhancement of oncolytic virus spread and antitumor efficacy. Clin. Cancer Res., 2011 17, 1362-1372.
99. Aghi, M.; Rabkin, S. D.; Martuza, R. L. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide. Cancer Res., 2007 67, 440-444.
100. Liu, T. C.; Castelo-Branco, P.; Rabkin, S. D.; Martuza, R. L. Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects. Mol. Ther., 2008 16, 1041-1047.
101. Kaur, B.; Khwaja, F. W.; Severson, E. A.; Matheny, S. L.; Brat, D. J.; Van Meir, E. G. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro-oncol., 2005 7, 134-153.
102. Fasullo, M.; Burch, A. D.; Britton, A. Hypoxia enhances the replication of oncolytic herpes simplex virus in p53-breast cancer cells. Cell Cycle, 2009 8, 2194-2197.
103. Aghi, M K; Liu, T C; Rabkin, S; Martuza, R L. Hypoxia enhances the replication of oncolytic herpes simplex virus. Mol. Ther., 2009 17, 51-56.
104. Wakimoto, H.; Johnson, P. R.; Knipe, D. M.; Chiocca, E. A. Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene. Ther., 2003 10, 983-990.
105. Fulci, G.; Breymann, L.; Gianni, D.; Kurozomi, K.; Rhee, S. S.; Yu, J.; Kaur, B.; Louis, D. N.; Weissleder, R.; Caligiuri, M. A.; Chiocca, E. A. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc. Natl. Acad. Sci. USA, 2006 103, 12873-12878.
106. Fulci, G.; Dmitrieva, N.; Gianni, D.; Fontana, E. J.; Pan, X.; Lu, Y.; Kaufman, C. S.; Kaur, B.; Lawler, S. E.; Lee, R. J.; Marsh, C. B.; Brat, D. J.; van Rooijen, N.; Stemmer-Rachamimov, A. O.; Hochberg, F. H.; Weissleder, R.; Martuza, R. L.; Chiocca, E. A. Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res., 2007 67, 9398-9406.
107. Wakimoto, H.; Fulci, G.; Tyminski, E.; Chiocca, E. A. Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis. Gene Ther., 2004 11, 214-223.
108. Lamfers, M. L.; Fulci, G.; Gianni, D.; Tang, Y.; Kurozumi, K.; Kaur, B.; Moeniralm, S.; Saeki, Y.; Carette, J. E.; Weissleder, R.; Vandertop, W. P.; van Beusechem, V. W.; Dirven, C. M.; Chiocca, E. A. Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging. Mol. Ther., 2006 14, 779-788.
109. Klotzbucher, A.; Mittnacht, S.; Kirchner, H.; Jacobsen, H. Different effects of IFN gamma and IFN alpha/beta on immediate early gene expression of HSV-1. Virology, 1990 179, 487-491.
110. Zhou, Y.; Ye, L.; Wan, Q.; Zhou, L.; Wang, X.; Li, J.; Hu, S.; Zhou, D.; Ho, W. Activation of Toll-like receptors inhibits herpes simplex virus-1 infection of human neuronal cells. J. Neurosci. Res., 2009 87, 2916-2925.
111. Wuest, T.; Austin, B. A.; Uematsu, S.; Thapa, M.; Akira, S.; Carr, D. J. Intact TRL 9 and type I interferon signaling pathways are required to augment HSV-1 induced corneal CXCL9 and CXCL10. J. Neuroimmunol., 2006 179, 46-52.
112. Mohr, I. Neutralizing innate host defenses to control viral translation in HSV-1 infected cells. Int. Rev. Immunol., 2004 23, 199-220.
113. Marques, C. P.; Cheeran, M. C.; Palmquist, J. M.; Hu, S.; Lokensgard, J. R. Microglia are the major cellular source of inducible nitric oxide synthase during experimental herpes encephalitis. J. Neurovirol., 2008 14, 229-238.